Pyxis Oncology Inc’s recently made public that its CFO and COO Connealy Pamela Ann acquired Company’s shares for reported $14960.0 on Sep 28 ’23. In the deal valued at $1.87 per share,8,000 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 818,532 shares worth roughly $3.27 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Connealy Pamela Ann bought 6,426 shares, generating $11,868 in total proceeds. Upon buying the shares at $1.85, the CFO and COO now owns 810,532 shares.
Before that, Wadhane Jitendra bought 2,500 shares. Pyxis Oncology Inc shares valued at $4,675 were divested by the Chief Accounting Officer at a price of $1.87 per share. As a result of the transaction, Wadhane Jitendra now holds 226,937 shares, worth roughly $0.91 million.
BTIG Research initiated its Pyxis Oncology Inc [PYXS] rating to a Buy in a research note published on February 09, 2024; the price target was $8. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late January with a ‘”an Outperform”‘ rating. RBC Capital Mkts began covering PYXS with “an Outperform” recommendation on September 05, 2023. Jefferies started covering the stock on November 02, 2021. It rated PYXS as “a Buy”.
Price Performance Review of PYXS
On Friday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock fall -19.56% to $3.99. Over the last five days, the stock has lost -22.07%. Pyxis Oncology Inc shares have risen nearly 121.67% since the year began. Nevertheless, the stocks have risen 81.36% over the past one year. While a 52-week high of $6.92 was reached on 02/27/24, a 52-week low of $1.35 was recorded on 01/02/24. SMA at 50 days reached $4.52, while 200 days put it at $2.71. A total of 1.06 million shares were traded, compared to the trading of 2.59 million shares in the previous session.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 3.60, which if violated will result in even more drops to 3.21. On the upside, there is a resistance level at 4.77. A further resistance level may holdings at 5.55. The Relative Strength Index (RSI) on the 14-day chart is 37.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 100.00%. Stochastics %K at 36.34% indicates the stock is a holding.
How much short interest is there in Pyxis Oncology Inc?
A steep rise in short interest was recorded in Pyxis Oncology Inc stocks on Feb 29, 2024, growing by 0.56 million shares to a total of 1.34 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 0.78 million shares. There was a rise of 41.45%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 3.64% of the overall stock float, the days-to-cover ratio (short ratio) rose to 1.42.
The most recent change occurred on November 02, 2021 when Credit Suisse began covering the stock and recommended ‘”an Outperform”‘ rating along with a $19 price target.
